Free Trial

Aurinia Pharmaceuticals (AUPH) News Today

Aurinia Pharmaceuticals logo
$8.01 +0.27 (+3.49%)
As of 01/17/2025 04:00 PM Eastern
Aurinia Pharmaceuticals Inc. stock logo
Barclays PLC Increases Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Barclays PLC lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 187.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 219,331 shares of the biotechnology compa
Aurinia Pharmaceuticals Inc. stock logo
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy Rating
StockNews.com upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday.
Aurinia Pharmaceuticals Inc. stock logo
Franklin Resources Inc. Sells 75,024 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Franklin Resources Inc. cut its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 78.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,253 shares of the biotechnology company's st
Aurinia Pharmaceuticals Inc. stock logo
Barclays PLC Buys 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Barclays PLC increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 187.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 219,331 shares of the biotechnology company's stock after buying
Aurinia Pharmaceuticals Inc. stock logo
State Street Corp Has $21.59 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
State Street Corp grew its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 2.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,945,060 shares of the biotechnology company's stock after buying
Aurinia Pharmaceuticals Inc. stock logo
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Update
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 6,220,000 shares, a decline of 9.6% from the November 15th total of 6,880,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 4.9 days.
Insiders Are Loving These 6 Stocks Right Now
Aurinia Pharmaceuticals Inc. stock logo
Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.com
StockNews.com cut shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday.
Aurinia Pharmaceuticals Inc. stock logo
Charles Schwab Investment Management Inc. Acquires 89,940 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Charles Schwab Investment Management Inc. grew its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 13.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 744,050 shares of
Aurinia Pharmaceuticals Inc. stock logo
PDT Partners LLC Has $2.21 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
PDT Partners LLC lifted its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 76.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 301,553 shares of the biotechnology company's stock after acquiring an
Aurinia Pharmaceuticals Inc. stock logo
Algert Global LLC Sells 65,791 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Algert Global LLC lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 33.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 128,013 shares of the biotechnology company's stock after selling 65,791 shares dur
Aurinia Pharmaceuticals Inc. stock logo
Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 454,259 shares of the biotechnol
Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
Aurinia Pharmaceuticals Inc. stock logo
GSA Capital Partners LLP Sells 102,373 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
GSA Capital Partners LLP cut its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 44.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 125,645 shares of the biote
Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024
Aurinia Pharmaceuticals Engages at London Conference
Aurinia Pharmaceuticals Inc. stock logo
Research Analysts Offer Predictions for AUPH Q1 Earnings
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of Aurinia Pharmaceuticals in a note issued to investors on Thursday, November 7th. Leerink Partnrs analyst J. Schwartz now anti
Aurinia Pharmaceuticals Inc. stock logo
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com
StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday.
Aurinia Pharmaceuticals Inc. stock logo
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% - Should You Buy?
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% - Should You Buy?
Aurinia Pharmaceuticals Inc. stock logo
Aurinia Pharmaceuticals (AUPH) Scheduled to Post Earnings on Thursday
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.
Aurinia Pharmaceuticals Inc. stock logo
AQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
AQR Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 202,241 shares of the biotechnolog
Aurinia Pharmaceuticals Inc. stock logo
SG Americas Securities LLC Grows Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
SG Americas Securities LLC grew its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 4,307.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 547,727
Aurinia Pharmaceuticals Inc. stock logo
Algert Global LLC Acquires 100,104 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Algert Global LLC lifted its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 106.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 193,804 shares of the biotechnology compa
Aurinia Pharmaceuticals Inc. stock logo
Stonepine Capital Management LLC Takes $1.71 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Stonepine Capital Management LLC bought a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 300,000 shares of the biotech
Aurinia Pharmaceuticals Inc. stock logo
Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 13.0%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 7,580,000 shares, a drop of 13.0% from the August 31st total of 8,710,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the days-to-cover ratio is presently 5.3 days.
Aurinia Pharmaceuticals Inc. stock logo
Armistice Capital LLC Lowers Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Armistice Capital LLC reduced its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 9.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,136,000 shares of the b
Aurinia Pharma Gets Approval in Japan for Lupus Treatment
Aurinia Announces Approval Of LUPKYNIS In Japan - Quick Facts
Get Aurinia Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

AUPH Media Mentions By Week

AUPH Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AUPH
News Sentiment

1.01

0.44

Average
Medical
News Sentiment

AUPH News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AUPH Articles
This Week

1

3

AUPH Articles
Average Week

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AUPH) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners